Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

NCT00634881 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Alemtuzumab i.v.
BIOLOGICAL: Alemtuzumab s.c.

Sponsor

German CLL Study Group